Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
Adenosine Diphosphate
/ pharmacology
Adenosine Monophosphate
/ administration & dosage
Administration, Oral
Aged
Aged, 80 and over
Area Under Curve
Aspirin
/ therapeutic use
Cardiac Catheterization
Comorbidity
Female
Heart
/ physiopathology
Humans
Infusions, Intravenous
Male
Mastication
Middle Aged
Percutaneous Coronary Intervention
Platelet Aggregation
/ drug effects
Polypharmacy
Prasugrel Hydrochloride
/ administration & dosage
Proportional Hazards Models
Purinergic P2Y Receptor Antagonists
/ administration & dosage
ST Elevation Myocardial Infarction
/ drug therapy
Tablets
Tirofiban
/ administration & dosage
Treatment Outcome
cangrelor
percutaneous coronary intervention
platelet aggregation
prasugrel hydrochloride
tirofiban
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
04 08 2020
04 08 2020
Historique:
entrez:
16
8
2020
pubmed:
17
8
2020
medline:
2
9
2021
Statut:
ppublish
Résumé
Standard administration of newer oral P2Y The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in Patients with ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention) is an investigator-initiated, multicenter, open-label, randomized study. A total of 122 P2Y At 30 minutes, cangrelor did not satisfy noninferiority compared with tirofiban, which yielded superior IPA over cangrelor (95.0±8.9 versus 34.1±22.5; Cangrelor provided inferior IPA compared with tirofiban; both treatments yielded greater IPA compared with chewed prasugrel, which led to higher active metabolite concentration but not greater IPA compared with integral prasugrel. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02978040; URL: https://www.clinicaltrialsregister.eu; EudraCT 2017-001065-24.
Sections du résumé
BACKGROUND
Standard administration of newer oral P2Y
METHODS
The FABOLUS-FASTER trial (Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in Patients with ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention) is an investigator-initiated, multicenter, open-label, randomized study. A total of 122 P2Y
RESULTS
At 30 minutes, cangrelor did not satisfy noninferiority compared with tirofiban, which yielded superior IPA over cangrelor (95.0±8.9 versus 34.1±22.5;
CONCLUSIONS
Cangrelor provided inferior IPA compared with tirofiban; both treatments yielded greater IPA compared with chewed prasugrel, which led to higher active metabolite concentration but not greater IPA compared with integral prasugrel. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02978040; URL: https://www.clinicaltrialsregister.eu; EudraCT 2017-001065-24.
Identifiants
pubmed: 32795098
doi: 10.1161/CIRCULATIONAHA.120.046928
pmc: PMC7392586
doi:
Substances chimiques
Purinergic P2Y Receptor Antagonists
0
Tablets
0
Adenosine Monophosphate
415SHH325A
Adenosine Diphosphate
61D2G4IYVH
cangrelor
6AQ1Y404U7
Prasugrel Hydrochloride
G89JQ59I13
Tirofiban
GGX234SI5H
Aspirin
R16CO5Y76E
Banques de données
EudraCT
['2017-001065-24']
ClinicalTrials.gov
['NCT02978040']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-454Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Références
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
J Clin Med. 2020 Feb 21;9(2):
pubmed: 32098088
Platelets. 2020;31(2):174-178
pubmed: 31502505
J Thromb Haemost. 2019 Jun;17(6):944-950
pubmed: 30884109
J Am Coll Cardiol. 2010 Sep 14;56(12):919-33
pubmed: 20828644
J Am Coll Cardiol. 2016 May 3;67(17):1994-2004
pubmed: 27012781
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
Am Heart J. 2006 Mar;151(3):689.e1-689.e10
pubmed: 16504633
JACC Cardiovasc Interv. 2017 Jan 23;10(2):121-129
pubmed: 28104204
J Am Coll Cardiol. 2015 Feb 10;65(5):511-2
pubmed: 25660931
J Am Coll Cardiol. 2013 Apr 16;61(15):1601-6
pubmed: 23500251
J Am Coll Cardiol. 2016 Mar 15;67(10):1235-1250
pubmed: 26498666
Thromb Haemost. 2019 Jul;119(7):1171-1181
pubmed: 31129911
Rapid Commun Mass Spectrom. 2007;21(2):169-79
pubmed: 17154350
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):151-157
pubmed: 30698669
Circulation. 2004 Sep 14;110(11):1392-7
pubmed: 15313953
Am J Cardiol. 2002 Mar 1;89(5):647-50
pubmed: 11867064
JACC Cardiovasc Interv. 2012 Mar;5(3):268-77
pubmed: 22440491
J Am Coll Cardiol. 2009 Mar 10;53(10):849-56
pubmed: 19264241
Thromb Haemost. 2001 Mar;85(3):401-7
pubmed: 11307804
J Cardiovasc Transl Res. 2020 Feb 24;:
pubmed: 32096064
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Circulation. 2017 Nov 14;136(20):1955-1975
pubmed: 29084738
J Am Coll Cardiol. 2010 Oct 26;56(18):1447-55
pubmed: 20951320
N Engl J Med. 1993 Sep 2;329(10):673-82
pubmed: 8204123
N Engl J Med. 2007 Dec 13;357(24):2482-94
pubmed: 18077812
Circulation. 2019 Apr 2;139(14):1661-1670
pubmed: 30630341
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537
pubmed: 31202949
J Am Coll Cardiol. 2006 Dec 5;48(11):2178-85
pubmed: 17161242
J Am Coll Cardiol. 2018 Oct 2;72(14):1750-1751
pubmed: 30261967
Thromb Res. 2017 Jan;149:88-94
pubmed: 27773347
Eur Heart J. 2014 Jan;35(4):209-15
pubmed: 24067509
Curr Drug Targets. 2014;15(7):720-8
pubmed: 24845219
Expert Rev Cardiovasc Ther. 2009 Oct;7(10):1195-201
pubmed: 19814662
Circ Cardiovasc Interv. 2012 Dec;5(6):797-804
pubmed: 23169985
Circulation. 2018 Jun 12;137(24):2635-2650
pubmed: 29891620
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Circulation. 2017 Aug 29;136(9):817-833
pubmed: 28637879
J Am Coll Cardiol. 1988 Jan;11(1):1-11
pubmed: 3121710